Most people think of bone loss as a calcium problem. Take your supplements, drink your milk, and everything should be fine. But the primary drivers of bone loss with age are hormonal, not nutritional. Estrogen and testosterone actively maintain bone density throughout adult life, and when these hormones decline — whether from menopause, andropause, surgical removal of the gonads, or any other cause — bone resorption accelerates in ways that calcium supplementation alone cannot offset.
Understanding exactly what estrogen and testosterone do for bone, why their decline is so damaging, and what the evidence shows about hormone therapy as a bone-protective intervention is clinically important for anyone approaching midlife. Osteoporosis is not a cosmetic concern: it is a leading cause of disability and mortality in adults over 65, and its origins are almost always traceable to hormonal shifts that began years or decades earlier.
Quick answer
Estrogen is the primary bone-protective hormone in both men and women. It works by suppressing osteoclast activity — the cells that break down bone. Testosterone protects bone both directly and indirectly, primarily through its conversion to estradiol in bone tissue. When either hormone declines significantly, bone resorption outpaces bone formation and density falls. Postmenopausal women lose bone at 1 to 3 percent per year in the years immediately following menopause. Men with hypogonadism have osteoporosis rates comparable to postmenopausal women. Hormone therapy — when appropriate for the individual — is among the most effective bone-protective interventions available.
How Bone Remodeling Works — and Why Hormones Drive It
Bone is not a static material. It is living tissue that undergoes continuous remodeling throughout life through the coordinated activity of two cell types: osteoblasts, which build new bone, and osteoclasts, which break old bone down. This process of bone resorption and bone formation is normally in balance, maintaining density and replacing micro-damaged tissue. The balance is regulated primarily by hormones.
Estrogen is the dominant regulator of this balance. It suppresses osteoclast activity, promotes osteoclast apoptosis, and supports osteoblast survival. When estrogen levels fall, osteoclast activity surges unchecked, bone resorption accelerates, and the net result is progressive bone loss. This is why the years immediately following menopause are the period of fastest bone loss in a woman’s lifetime.
Testosterone contributes to bone health through both direct and indirect mechanisms. Directly, testosterone receptors on osteoblasts stimulate bone formation, particularly in cortical (outer) bone. Indirectly, testosterone is converted to estradiol via aromatase in bone tissue, and this local estradiol production drives many of testosterone’s bone-protective effects.
Bone Remodeling: The Hormonal Balance
🦴
Osteoblasts
Build new bone tissue. Stimulated by estrogen, testosterone, and mechanical loading.
BONE FORMATION ↑
⇌
Balance
⚠️
Osteoclasts
Break down old bone. Activity surges when estrogen falls — primary driver of postmenopausal bone loss.
BONE RESORPTION ↑
Tips balance toward BUILD
Optimal estradiol levels
Adequate testosterone
Resistance exercise
Sufficient vitamin D and calcium
Tips balance toward BREAKDOWN
Estrogen deficiency (menopause)
Low testosterone / hypogonadism
Elevated cortisol, corticosteroids
Vitamin D deficiency, sedentary lifestyle
The RANKL pathway: how estrogen controls bone resorption
Estrogen regulates bone remodeling primarily through the RANK/RANKL/OPG signaling axis. RANKL stimulates osteoclast development; OPG blocks it. Estrogen increases OPG and decreases RANKL. When estrogen falls, RANKL rises, OPG falls, and osteoclast activity surges. This molecular mechanism explains why even modest estrogen decline translates into measurable bone loss — and why pharmaceutical agents targeting RANKL (such as denosumab) produce effects similar to estrogen replacement on bone turnover markers.
Menopause and Bone Loss: The Timeline That Starts Earlier Than Most Expect
The most rapid phase of bone loss in women occurs in the perimenopause and early postmenopause period — typically beginning 1 to 2 years before the final menstrual period and continuing for approximately 5 to 10 years afterward. During this window, bone mineral density can fall 1 to 3 percent per year in trabecular bone (the spongy inner bone of the spine and hip).
The cumulative picture is striking. A woman who enters menopause at age 50 and is never evaluated or treated may lose 15 to 20 percent of her total bone mass by age 65. Hip fracture in women over 65 carries a one-year mortality rate of approximately 20 to 25 percent — not from the fracture itself, but from cascading complications of immobility, hospitalization, pneumonia, and cardiovascular events.
Phases of Bone Loss in Women: Hormonal Context
Premenopause
Ages 20–44
<0.5%
per year — stable estradiol; bone balance maintained
Perimenopause
Ages 45–52
0.5–1%
per year — estradiol fluctuating; FSH rising
Early Menopause
Years 1–5
1–3%
per year — abrupt estrogen withdrawal; max RANKL activity
Late Menopause
Years 5+
0.5–1%
per year — secondary loss via PTH; low adrenal DHEA
Trabecular bone (spine, hip) is lost faster than cortical bone. Individual rates vary based on genetics, body composition, physical activity, and hormonal history.
Women who begin hormone therapy in the perimenopause or early postmenopause can largely halt this phase of accelerated bone loss. Those who start later still gain benefit, but the bone lost in the untreated window cannot be fully recovered — which makes the timing of evaluation critically important. For more on what the transition into menopause looks like hormonally, see our article on HRT vs bioidentical hormones.
Men Are Not Protected: Testosterone, Estrogen, and Male Bone
Osteoporosis is often framed as a women’s disease, but approximately one in four men over the age of 50 will experience an osteoporosis-related fracture in their lifetime. Male bone health is equally hormone-dependent — and perhaps more nuanced, because both testosterone and estrogen play distinct roles that are lost when either declines.
Studies using estrogen receptor knockout models in men have demonstrated that estradiol, not testosterone, is the dominant hormone regulating bone resorption in men as well as women. Men with aromatase deficiency — who cannot convert testosterone to estrogen — develop severe osteoporosis despite having normal or elevated testosterone levels, and their bone loss responds to estrogen replacement but not to testosterone administration alone. Estradiol thresholds below approximately 25 pg/mL in men are strongly associated with accelerated bone resorption regardless of testosterone status.
Often missed in men: the estradiol threshold
When evaluating a man’s bone health, testosterone alone is not a sufficient marker. Estradiol below 25 pg/mL predicts bone loss and fracture in men independently of testosterone. A man with testosterone in the normal range but low estradiol — due to poor aromatase activity, aromatase inhibitor use, or very low body fat — may have significant bone loss that a testosterone-only evaluation would miss entirely. A complete male hormonal panel for bone health should include estradiol (sensitive LC-MS/MS assay), testosterone, SHBG, and bone turnover markers CTX and P1NP. See our article on how to read your hormone lab results.
How Sex Hormones Protect Bone: Women vs Men
Women
Primary protector: Estradiol — suppresses osteoclasts via RANKL/OPG
Secondary: Testosterone — cortical bone formation, converted to estradiol locally
High-risk threshold: Estradiol <25 pg/mL regardless of testosterone level
Hormone Therapy and Bone Protection: What the Evidence Shows
The evidence that hormone therapy preserves bone density in postmenopausal women is among the most robust in endocrinology. Multiple randomized controlled trials, including the Women’s Health Initiative (WHI), confirm that estrogen therapy significantly reduces bone resorption markers, increases bone mineral density at the spine and hip, and reduces fracture risk. The WHI demonstrated a 34 percent reduction in hip fractures and a 24 percent reduction in total fractures in women receiving combined estrogen-progestogen therapy.
Hormone Therapy and Bone: Evidence Summary
Estrogen in postmenopausal women
Reduces bone resorption markers 30–50%. Increases spine BMD 3–5% over 2 years. WHI: 34% reduction in hip fractures, 24% reduction in all fractures.
Evidence: Strong (RCT level)
Testosterone in hypogonadal men
Consistent increases in lumbar spine and femoral neck BMD of 2–8% over 1–3 years. Fracture data limited but mechanistic basis and density improvements are strong.
Evidence: Moderate-strong
Testosterone added to HRT in women
Several RCTs show additive bone density benefit when testosterone is added to estrogen therapy in postmenopausal women, particularly for cortical bone sites.
Evidence: Moderate
Timing: the window of opportunity
Starting estrogen within 5 years of menopause provides the greatest bone benefit. Later initiation still protects bone but does not recover already-lost density.
Evidence: Strong (observational + RCT)
What happens when hormone therapy is stopped
The bone-protective effect of estrogen is not durable after discontinuation. Studies following women who stopped hormone therapy show accelerated bone loss in the years immediately following cessation, with loss rates approaching those seen at menopause onset. Women who discontinue hormone therapy without transitioning to an alternative bone-protective agent may lose a significant portion of the density benefit within 2 to 3 years.
Measuring and Monitoring Bone Health
Bone mineral density (BMD) measurement via DEXA scan is the standard method for diagnosing osteopenia and osteoporosis and monitoring response to treatment. Results are reported as T-scores (comparison to young adult peak bone mass) and Z-scores (comparison to age-matched peers).
DEXA T-Score Interpretation
T-Score
Classification
Clinical meaning
-1.0 and above
Normal
Bone density within expected range for young adults
-1.0 to -2.5
Osteopenia
Below normal; elevated fracture risk without treatment
T-scores are used for postmenopausal women and men over 50. Z-scores (age-matched comparison) are used for younger adults and premenopausal women.
Bone turnover markers — blood tests that reflect the rate of bone resorption and formation — provide dynamic information that DEXA cannot. The most clinically useful markers are CTX (C-terminal telopeptide, a resorption marker) and P1NP (procollagen type 1 N-terminal propeptide, a formation marker). In a patient who has recently become estrogen-deficient, elevated CTX confirms active accelerated resorption even before DEXA shows significant density loss.
Who should be evaluated now — not at the first fracture
Current guidelines recommend DEXA screening starting at age 65 in women and 70 in men — but this was designed for the general population without hormonal context. Women with early menopause (before 45), premature ovarian insufficiency, surgical menopause, or significant estrogen deficiency symptoms should have DEXA evaluation earlier — ideally within 1 to 2 years of the onset of deficiency. Men with hypogonadism, a history of androgen deprivation therapy, or estradiol below 20 pg/mL should also be evaluated earlier. A fracture after 50 — especially of the wrist, spine, or hip — is a major red flag that should trigger immediate hormonal evaluation regardless of age or sex.
Beyond Hormones: The Full Picture of Bone Health
Hormone status is the dominant determinant of bone loss with age, but several co-factors meaningfully modify the hormonal impact on bone and should be addressed alongside hormonal optimization.
Vitamin D and calcium
Vitamin D deficiency impairs calcium absorption and secondarily causes hyperparathyroidism, which drives bone resorption independently of sex hormones. Target 25-OH vitamin D: 40–60 ng/mL. Dietary calcium is preferable to supplementation for most adults.
Resistance exercise
Weight-bearing and resistance exercise stimulate osteoblast activity through mechanical loading. Exercise does not compensate for estrogen deficiency, but substantially modifies bone loss rate and reduces fall risk — the proximate cause of most osteoporotic fractures.
Cortisol and chronic stress
Elevated cortisol suppresses osteoblast function, reduces calcium absorption, and increases RANKL expression. Patients on long-term corticosteroids are at high risk for glucocorticoid-induced osteoporosis, which progresses rapidly and silently. See our article on cortisol and the stress hormone connection.
Thyroid status and body weight
TSH below 0.5 mIU/L — from hyperthyroidism or overtreatment — is an independent risk factor for bone loss. Low body weight and low lean mass significantly amplify the bone consequences of hormonal decline.
Frequently Asked Questions
At what age does hormonal bone loss actually begin?
For women, measurable accelerated bone loss begins in perimenopause — typically 1 to 2 years before the final menstrual period, usually in the mid-to-late 40s. The fastest phase occurs in the first 5 years after menopause. For men, significant bone loss typically begins when testosterone and estradiol decline below critical thresholds, usually in the late 50s to 60s — though men with early hypogonadism can experience significant bone loss much earlier. Bone lost cannot be fully restored by any intervention currently available, which makes early evaluation important.
Does hormone therapy prevent fractures or only improve bone density numbers?
Both. The WHI clinical trial demonstrated a 34 percent reduction in hip fractures, 24 percent reduction in total fractures, and 34 percent reduction in clinical vertebral fractures compared to placebo. These are fracture outcomes, not just DEXA numbers. For testosterone therapy in hypogonadal men, the fracture evidence is less complete but the consistent BMD increases and mechanistic basis for bone protection are strong.
If I already have osteopenia, can hormone therapy reverse it?
Hormone therapy can meaningfully increase bone density in women with osteopenia. Studies consistently show 3 to 5 percent gains in lumbar spine BMD and 1 to 3 percent at the femoral neck over 2 years of estrogen therapy. Whether that improvement moves someone from the osteopenic range back to normal depends on where they started and how long they were estrogen-deficient before treatment. For women with established osteoporosis who also have symptomatic hormone deficiency, hormone therapy can be combined with bisphosphonates or other bone-specific agents — the two approaches work through different mechanisms and are not mutually exclusive.
I take calcium and vitamin D. Is that enough to protect my bones through menopause?
No. Calcium and vitamin D are necessary co-factors but do not address the underlying hormonal mechanism of postmenopausal bone loss. Estrogen deficiency drives bone loss through the RANK/RANKL pathway — a cellular signaling mechanism that calcium supplementation does not modulate. Think of it this way: calcium provides the building material, but estrogen is the signal that tells osteoclasts to stop destroying the structure. Without estrogen, osteoclast activity continues unrestrained regardless of how much calcium is available.
How often should I get a DEXA scan?
For women at average risk: baseline at menopause or age 50, then repeat every 2 years if in the osteopenic range or if a new risk factor arises. Women on hormone therapy with normal baseline BMD may extend the interval to 5 years. Women with established osteoporosis are typically monitored every 1 to 2 years. For men with hypogonadism: a baseline at diagnosis, repeat testing at 1 to 2 years after starting testosterone therapy to confirm response.
Can low testosterone cause osteoporosis in men under 50?
Yes, and this is an underdiagnosed problem. Men with primary or secondary hypogonadism beginning in their 20s or 30s — whether from testicular failure, pituitary disease, or other causes — can develop significant osteopenia or osteoporosis well before standard screening ages. Studies of men with long-standing untreated hypogonadism show BMD losses comparable to those seen in postmenopausal women. Any man under 55 who fractures a bone with minimal trauma should have testosterone and estradiol assessed as part of the evaluation.
What is the first appointment like if I want to get my bone health and hormones evaluated?
A thorough evaluation combines lab work, a DEXA referral if not recently completed, a detailed symptom and history review, and assessment of contributing factors such as medications, thyroid status, and body composition. The lab panel should include estradiol (sensitive assay), total and free testosterone, SHBG, DHEA-S, 25-OH vitamin D, calcium, PTH, TSH, and bone turnover markers CTX and P1NP. For a detailed overview of what to bring and what to expect, see our article on your first hormone therapy appointment.
Concerned about bone loss and your hormone levels?
Our team evaluates bone health in the context of a complete hormonal picture — not just calcium and vitamin D. Whether you are approaching menopause, have recently been diagnosed with osteopenia, or want to understand your long-term fracture risk, we can help you build a plan based on your actual labs and clinical picture.
This article is for informational and educational purposes only and does not constitute medical advice, a diagnosis, or a treatment recommendation. Bone density measurement and hormone therapy decisions require individual clinical evaluation by a licensed healthcare provider. Hormone therapy is not appropriate for all individuals and carries risks that must be weighed against benefits in the context of each person’s complete medical history. DEXA screening recommendations should be applied by a qualified clinician. References to clinical trial data, including the Women’s Health Initiative, reflect published findings as of the date of this publication.
